Patient-Oriented Evidence That Matters
Platelet-Rich Plasma Is Equal to Saline for Patients with Patellar Tendinopathy
Am Fam Physician. 2019 Dec 15;100(12):online.
Are platelet-rich plasma injections effective in patients with patellar tendinopathy?
In this study, platelet-rich plasma injections were no better than saline injections in improving pain or activity in patients with patellar tendinopathy. It did not matter whether the plasma was leukocyte rich or leukocyte poor. The study was too small to detect potential harms of the intervention. (Level of Evidence = 2b)
In this multicenter (Seattle, Oslo, Bologna) trial, the authors enrolled 61 adults, 18 to 50 years of age, with at least six months of clinically diagnosed patellar tendinopathy confirmed by ultrasonography with persistent symptoms in spite of a minimum of six weeks of exercise-based rehabilitation. The authors randomized patients to receive ultrasound-guided injections of either leukocyte-rich platelet-rich plasma, leukocyte-poor platelet-rich plasma, or saline. One week later, all patients engaged in a supervised gym-based rehabilitation program three times weekly for six weeks. Using standardized scales, the researchers evaluated each patient's pain, function, and activity limitations at baseline, and at 12, 24, and 52 weeks after the injections. They asked the patients for their own overall rating of change at the subsequent assessments. They had nearly complete (93%) follow-up at 12 weeks but only 79% at the end of a year. At no point in the study did the authors find any differences in the three groups as to any of the outcomes or patient global assessment of improvement. Six weeks after the intervention, five patients, none of whom received saline, reported overall worsening compared with their baseline. The authors report one patient experienced localized patellar tendon pain following the injection, enough to prevent activity. No other harms are reported, possibly because of the small sample size. The study was large enough to detect clinically meaningful differences in pain and functional limitations.
Study design: Randomized
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, editor-in-chief.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions